# HLA-DOB

## Overview
HLA-DOB is a gene that encodes the beta chain of the major histocompatibility complex, class II, DO beta protein, which is a non-classical MHC class II-like protein. This protein is primarily involved in the immune system's antigen presentation process, functioning within the endosomal/lysosomal compartments of antigen-presenting cells such as B cells and thymic epithelial cells. HLA-DO, the heterodimer formed by HLA-DOB and HLA-DOA, interacts with HLA-DM to modulate the peptide loading of MHC class II molecules, thereby influencing the diversity of the peptides presented to the immune system. This modulation is crucial for maintaining immune tolerance and response diversity. The expression of HLA-DOB is regulated by the class II transactivator (CIITA) and potentially other mechanisms, reflecting its complex role in immune regulation (Liljedahl1996HLADO; Nanaware2019HLADO; Nagarajan2002Class).

## Function
HLA-DOB encodes the beta chain of the HLA-DO heterodimer, which plays a crucial role in modulating antigen presentation in the immune system. HLA-DO is a non-classical MHC class II-like protein that primarily functions within the endosomal/lysosomal compartments of antigen-presenting cells, such as B cells and thymic epithelial cells (Liljedahl1996HLADO; Nagarajan2002Class). It forms a stable complex with HLA-DM, a molecule involved in the peptide loading of MHC class II molecules. This interaction is essential for the efficient transport of HLA-DO from the endoplasmic reticulum to lysosomes (Liljedahl1996HLADO).

HLA-DO modulates the activity of HLA-DM by inhibiting its peptide loading function, which affects the diversity of the MHC-II self-peptidome. This inhibition allows for the presentation of a broader range of peptides, including those with lower affinity, thereby influencing immune responses and potentially contributing to self-tolerance (Nanaware2019HLADO; Kropshofer1998A). The expression of HLA-DOB is regulated by the class II transactivator (CIITA), although it can also occur independently, suggesting additional regulatory mechanisms (Nagarajan2002Class).

## Clinical Significance
HLA-DOB, a component of the HLA-DO complex, plays a role in modulating antigen presentation by controlling peptide loading onto MHC class II molecules. Alterations in HLA-DOB expression and mutations have been associated with various clinical conditions. In ovarian cancer, higher mRNA expression levels of HLA-DOB are linked to a better prognosis, suggesting its potential as a prognostic biomarker (Li2020Clinical). However, high expression levels have also been associated with a negative impact on overall survival in patients with advanced-stage ovarian cancer, indicating a complex role in disease progression (Li2020Clinical).

Polymorphisms in HLA-DOB have been implicated in the susceptibility to Hepatitis C Virus (HCV) infection. The rs2071469 G allele is associated with increased susceptibility to HCV, highlighting the gene's role in influencing infection outcomes (Huang2015Association). Despite these associations, the role of HLA-DOB in autoimmune diseases and B-cell leukemias appears limited, as studies have found minimal sequence variation and no critical involvement in these conditions (van2002Novel). The gene's expression and polymorphisms may influence immune responses, impacting disease susceptibility and progression.

## Interactions
HLA-DOB is involved in the formation of a heterodimer with HLA-DOA, collectively known as HLA-DO, which interacts with HLA-DM. This interaction is crucial for modulating the peptide loading of MHC class II molecules. HLA-DO forms tight complexes with HLA-DM in lysosome-like organelles within B cells, influencing the peptide loading process by promoting the loading of MHC class II molecules that depend on the chaperone activity of HLA-DM (Kropshofer1998A). The HLA-DO and HLA-DM complex is more effective than HLA-DM alone in stabilizing empty DR molecules, particularly in acidic compartments, which are typical of lysosomal environments (Kropshofer1998A).

HLA-DOB, as part of the HLA-DO complex, modulates the peptide editing function of HLA-DM, enhancing the stability and diversity of peptides bound to MHC class II molecules (Kropshofer1998A). The interaction between HLA-DO and HLA-DM is essential for maintaining the activity of HLA-DM and promoting peptide loading in an allele- and peptide-dependent manner (Kropshofer1998A). HLA-DOB's role in these interactions highlights its importance in antigen presentation and immune response regulation.


## References


[1. (Nanaware2019HLADO) Padma P. Nanaware, Mollie M. Jurewicz, John D. Leszyk, Scott A. Shaffer, and Lawrence J. Stern. Hla-do modulates the diversity of the mhc-ii self-peptidome. Molecular &amp; Cellular Proteomics, 18(3):490–503, March 2019. URL: http://dx.doi.org/10.1074/mcp.ra118.000956, doi:10.1074/mcp.ra118.000956. This article has 33 citations.](https://doi.org/10.1074/mcp.ra118.000956)

[2. (Nagarajan2002Class) Uma M. Nagarajan, Jonathan Lochamy, Xinjian Chen, Guy W. Beresford, Roger Nilsen, Peter E. Jensen, and Jeremy M. Boss. Class ii transactivator is required for maximal expression of hla-dob in b cells. The Journal of Immunology, 168(4):1780–1786, February 2002. URL: http://dx.doi.org/10.4049/jimmunol.168.4.1780, doi:10.4049/jimmunol.168.4.1780. This article has 35 citations.](https://doi.org/10.4049/jimmunol.168.4.1780)

[3. (Liljedahl1996HLADO) M. Liljedahl, T. Kuwana, W. P. Fung-Leung, M. R. Jackson, P. A. Peterson, and L. Karlsson. Hla-do is a lysosomal resident which requires association with hla-dm for efficient intracellular transport. The EMBO Journal, 15(18):4817–4824, September 1996. URL: http://dx.doi.org/10.1002/j.1460-2075.1996.tb00862.x, doi:10.1002/j.1460-2075.1996.tb00862.x. This article has 130 citations.](https://doi.org/10.1002/j.1460-2075.1996.tb00862.x)

[4. (Huang2015Association) Peng Huang, Yuanyuan Zhang, Xiaomei Lu, Yin Xu, Jie Wang, Yun Zhang, Rongbin Yu, and Jing Su. Association of polymorphisms in hla antigen presentation-related genes with the outcomes of hcv infection. PLOS ONE, 10(4):e0123513, April 2015. URL: http://dx.doi.org/10.1371/journal.pone.0123513, doi:10.1371/journal.pone.0123513. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0123513)

[5. (Li2020Clinical) Yanrong Li, Haixia Li, Baojun Yang, Jing Wei, Cheng Zhen, and Limin Feng. Clinical significance of pi3 and hla-dob as potential prognostic predicators for ovarian cancer. Translational Cancer Research, 9(2):466–476, February 2020. URL: http://dx.doi.org/10.21037/tcr.2019.11.30, doi:10.21037/tcr.2019.11.30. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.21037/tcr.2019.11.30)

[6. (Kropshofer1998A) H. Kropshofer. A role for hla-do as a co-chaperone of hla-dm in peptide loading of mhc class ii molecules. The EMBO Journal, 17(11):2971–2981, June 1998. URL: http://dx.doi.org/10.1093/emboj/17.11.2971, doi:10.1093/emboj/17.11.2971. This article has 98 citations.](https://doi.org/10.1093/emboj/17.11.2971)

[7. (van2002Novel) Marcel van Lith, Marieke van Ham, and Jacques Neefjes. Novel polymorphisms in hla-doa and hla-dob in b-cell malignancies. Immunogenetics, 54(8):591–595, November 2002. URL: http://dx.doi.org/10.1007/s00251-002-0500-6, doi:10.1007/s00251-002-0500-6. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00251-002-0500-6)